Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic imm… Read more
Kaleido Biosciences Inc (KLDO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2022: -1.618x
Based on the latest financial reports, Kaleido Biosciences Inc (KLDO) has a cash flow conversion efficiency ratio of -1.618x as of March 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.16 Million) by net assets ($10.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kaleido Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2021)
This chart illustrates how Kaleido Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kaleido Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kaleido Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Petrolimex Saigon
VN:PSC
|
N/A |
|
Supalai PCL
STU:NYVL
|
0.027x |
|
CN MINSHENG BK -H-
MU:GHFH
|
-0.242x |
|
C W Mackie PLC
CM:CWMN0000
|
N/A |
|
NB Distressed Debt Investment Fund Ltd
LSE:NBDD
|
-0.008x |
|
Credit Agricole Egypt
EGX:CIEB
|
N/A |
|
CHANGAN MINSHENG-H-
BE:W8R
|
N/A |
|
HBOR3F
SA:HBOR3F
|
N/A |
Annual Cash Flow Conversion Efficiency for Kaleido Biosciences Inc (2016–2021)
The table below shows the annual cash flow conversion efficiency of Kaleido Biosciences Inc from 2016 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-12-31 | $10.61 Million | $-77.09 Million | -7.268x | -142.16% |
| 2020-12-31 | $20.50 Million | $-61.52 Million | -3.001x | -93.57% |
| 2019-12-31 | $48.88 Million | $-75.80 Million | -1.551x | -94.82% |
| 2018-12-31 | $58.20 Million | $-46.32 Million | -0.796x | -254.54% |
| 2017-12-31 | $-43.68 Million | $-22.50 Million | 0.515x | -6.83% |
| 2016-12-31 | $-16.92 Million | $-9.35 Million | 0.553x | -- |